8 1 cascade could help us to design strategies to circumvent this resistance and develop more effective 8 2 inhibitors for cancer treatment. 8 3 The RAF kinases CRAF, BRAF and ARAF are a core component of the RAF/MEK/ERK kinase 8 4 cascade. Dimerization among RAF isoforms is a key event in triggering the RAF/MEK/ERK kinase 8 5 cascade 9-18 , which not only turns on the kinase activity of RAF but also facilitates the activation of MEK 8 6 by RAF 19 . Mechanistic studies have shown that the two protomers play distinct roles in RAF dimers: 8 7 one functions as an allosteric activator to facilitate the assembly of an active conformation in the other, 8 8 which acts as a receiver to catalyze the phosphorylation of substrates 20 . Distinct molecular traits 8 9
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The Ras/RAF/MEK/ERK signaling plays a crucial role in cell proliferation, survival, and been developed and applied to clinical treatment [6] [7] [8] . Unfortunately, their efficacy is limited by either 1 1 2
In this study, we characterized the RAF mutants with in-frame deletions in the β 3-αC loop, and 1 1 3
found that both ARAF and BRAF mutants were activated by enhanced dimerization. Further, we 1 1 4
showed that the limited allosteric and catalytic activities of ARAF arose from its non-canonical APE 1 1 5
motif that leads to a lower propensity of dimerization in contrast to BRAF and CRAF. Finally, we used 1 1 6
active RAF mutants with different dimerization properties as an efficient tool to investigate whether the 1 1 7 dimerization of RAF after activation is required for its catalytic activity and demonstrated that active 
4 7
To characterize BRAF mutants in Table S2 and determine whether they are activated by enhanced 2 4 8 homodimerization, we expressed these mutants in 293T cells and fibroblasts. All these mutants 2 4 9 stimulated the MEK-ERK pathway independent of upstream stimuli or endogenous RAF molecules 2 5 0 ( Figure 4A&B and S3A), indicating that they are constitutively active. However, these mutants exhibited 2 5 1 differential resistance to the central RH alteration (R509H) in dimer interface ( Figure 4C ). This alteration 2 5 2 had no effect on the activity of BRAF(ΔNVTAP), partially inhibited that of BRAF(ΔMLN), and completely 2 5 3 blocked that of BRAF(ΔNVTAPT). We reasoned that this discrepancy among BRAF mutants might arise 2 5 4 from their different dimer affinity/stability. To test this hypothesis, we carried out co-immunoprecipitation 2 5 5 assays, and found that indeed these mutants had enhanced but different propensities to form dimers, 2 5 6
with ΔNVTAP > ΔMLN > ΔNVTAPT ≈ ΔQA > WT, independently of ERK1/2-mediated feedback 46 2 5 7
( Figure 4D and S3B&C). The R509H alteration prevented the homodimerization of BRAF(ΔNVTAPT) 2 5 8 7 and BRAF(ΔQA), partially that of BRAF(ΔMLN), and weakly that of BRAF(ΔNVTAP). Previous studies 2 5 9
have shown that although the central Arginine alteration impairs the dimerization-driven transactivation 2 6 0 of wild-type RAFs 15 , it makes up less than 20% dimer interface 11 . Therefore, the resistance of 2 6 1 BRAF(ΔMLN) and BRAF(ΔNVTAP) to the central R509H alteration in dimer interface does not exclude 2 6 2 that these two BRAF mutants are activated through dimerization-driven transactivation by virtue of their 2 6 3 much stronger dimer affinity than wild-type counterpart. To further demonstrate that these BRAF 2 6 4 mutants, especially BRAF(ΔNVTAP) and BRAF(ΔMLN), are activated by enhanced 2 6 5 homodimerization, we performed the RAF co-activation assay 20, 36, 37, 40, 41 by using their kinase-dead 2 6 6 V471F mutants as allosteric activators. All activators tested in this study strongly stimulated the catalytic 2 6 7 activity of CRAF receivers ( Figure 4E ), and particularly activators derived from BRAF(ΔNVTAP) and R509H alteration in dimer interface was unable to prevent these two strong allosteric activators from 2 7 0 triggering BRAF receivers ( Figure S3D ). Since the non-canonical APE motif had been also shown to 2 7 1 decrease the dimer affinity in RAF molecules, we next introduced it together with the central R509H 2 7 2 alteration into BRAF(ΔNVTAP) mutant, and found that this combined alteration completely blocked the 2 7 3 activity of BRAF(ΔNVTAP) ( Figure S3E ). Taken together, our data demonstrates that all BRAF mutants 2 7 4
with in-frame deletions of β 3-αC loop are activated by enhanced homodimerization.
7 5
Unlike ARAF and BRAF, we did not find any CRAF mutants with in-frame deletions of β 3-αC loop 2 7 6
in databases. To test whether CRAF can be activated by this type of mutations, we constructed mutants 2 7 7 homologous to those of ARAF and BRAF. When expressed in 293T cells, ΔVDPT, ΔVDPTP, and 2 7 8
ΔVVDPT mutants of CRAF, but not other mutants, strongly activated the MEK-ERK pathway 2 7 9 independent of upstream stimuli ( Figure 4F and S3F&G), and exhibited differential resistance to the 2 8 0 central RH alteration (R401H) in dimer interface ( Figure 4G ). Since we had showed that BRAF was 2 8 1 activated by mutations (ΔQA and ΔQL) homologous to ARAF(ΔQA), we hence determined whether 2 8 2 ARAF could be triggered by mutations homologous to BRAF(ΔMLN, ΔNVTAP, ΔNVTAPT). However, 2 8 3 none of these alterations activated ARAF ( Figure S3H ). 
8 8
Although the oncogenic potential and resistance to RAF inhibitor of BRAF(ΔNVTAP) has been 2 8 9
reported recently 31, 34 , whether all BRAF mutants with in-frame deletions of β 3-αC loop are able to 2 9 0 function as cancer drivers and their pharmacological characteristics are not clear. To address these 2 9 1 questions, we first measured the oncogenic potential of these mutants by foci formation assays. As 2 9 2 shown in Figure 5A and S4A&B, all BRAF mutants with in-frame deletions of β 3-αC loop transformed 2 9 3 immortalized fibroblasts and induced foci formation independent of endogenous RAF molecules, 2 9 4
suggesting that they can function as drivers to induce cancers. Further, we examined their sensitivities 2 9 5
to the RAF inhibitor Vemurafenib, and found that all mutants exhibited a robust resistance to this drug, Figure 5B&C ), which correlates with their dimer affinity/stability. However, all these mutants had similar 2 9 8
sensitivities to the RAF dimer inhibitor, LY3009120, which are comparable with that of BRAF(V600E) in 2 9 9
A101D melanoma cell line ( Figure 5D&E ). 3 0 3
The inhibitor-loading has been shown to fuse the catalytic spine of RAF molecules, which can be strengthened the dimers of BRAF(ΔNVTAPT) and BRAF(ΔQA), respectively, by GST fusions 50 , and 3 2 7
found that it restored their catalytic activity in vitro ( Figure 6B ). This phenomenon was also seen with a 3 2 8
homologous ARAF mutant (ΔQA) whose in vitro catalytic activity was rescued by GST fusion (Figure   3 2 9 6C). As reported before 20, 51 and shown in this study, both alterations of the central RH in dimer 3 3 0
interface and the APE motif significantly impair but do not completely abolish the dimer formation of 3 3 1 RAF molecules. We therefore next examined the effect of these alterations on the in vitro catalytic 3 3 2 activity of active RAF mutants. Among three active ARAF R-spine mutants, only the one with a high 3 3 3 dimer affinity (see Figure 3J -K) maintained its catalytic activity in vitro after purification ( Figure 6D) , and 3 3 4
GST fusion restored that of the other two mutants with a low dimer affinity ( Figure 6E ). Similar to that of 3 3 5 ARAF mutants, active CRAF mutants with an alteration of RH, or of APE, lost their catalytic activity in 3 3 6
vitro, which was recovered by GST fusion-enhanced dimerization ( Figure 6F ). As to active BRAF 3 3 7 9 R-spine mutants, the alterations of R509H, or APE, inhibited their catalytic activity in vitro by different 3 3 8
extends, which was also relieved by the GST fusion approach ( Figure 6G ). The loss of in vitro catalytic 3 3 9
activity of RAF mutants with low dimer affinity could be also rescued by other dimeric molecular fusions 3 4 0 (data not shown), or partially restored with a gentle wash of PBS during purification ( Figure S5) (Figure 7A ). Since 3 5 6 BRAF utilizes two different groups of residues to bind MEK and RAF 19 , the introduction of these 3 5 7 mutations would not influence RAF dimerization. Unlike its prototype, the mutant, no allosteric ability to trigger endogenous RAF molecules when expressed in 293T cells ( Figure 7B ).
6 0
Moreover, BRAF(V600E) bound to BRAF(ΔNVTAP/V471F)* had little catalytic activity in vitro, in 3 6 1 contrast to that bound to BRAF(ΔNVTAP/V471F) when purified from 293T co-transfectants ( Figure 7C ).
6 2
This suggests that a BRAF(V600E) molecule needs a partner able to hold MEK in order to 3 6 3 phosphorylate it. To further confirm this finding, we introduced BRAF(ΔNVTAP/V471F)* into 3 6 4 BRAF(V600E)-dependent melanoma cell lines by lentiviral transductions and found that its expression 3 6 5
down-regulated phospho-ERK1/2 and inhibited cell growth in vitro and xenograft tumor growth in vivo 3 6 6 ( Figure 7D -H).
6 7
As shown above, the APE motif of RAF kinases regulates their dimerization, likely through affecting 3 6 8
the Glu-Arg salt bridge between the APE motif and the αH-αI loop, and the alteration of APE motif into 3 6 9 non-canonical AAE dramatically decreases RAF dimer affinity/stability. Therefore, we next determined and R509H completely blocked the activity of BRAF(V600E) even in vivo, which was also recovered by 3 7 6
GST fusion ( Figure 7I ). To directly confirm that the discrepant catalytic activity among BRAF(V600E), 3 7 7 1 0 BRAF(V600E/AAE), and BRAF(V600E/AAE/R509H), arises from their different dimer affinity/stability, 3 7 8
we completed a co-immonprecipitation assay with a gentle wash of PBS as in Figure S5 , and found that 3 7 9 these BRAF variants had quite different ability to form dimers as BRAF(V600E) >> BRAF(V600E/AAE) 3 8 0 >> BRAF(V600E/AAE/R509H) ( Figure S6B ). Altogether, these data demonstrate that like other RAF 3 8 1 molecules, BRAF(V600E) also functions as a dimer to activate MEK. The dimerization of RAF kinase not only plays a critical role in the activation of the RAF/MEK/ERK 3 8 5 kinase cascade 9-17 , but also contributes to drug resistance in cancer therapy 11, 12, 14, 26 . Previous studies 3 8 6
have shown that the RAF dimerization could be improved by active RAS, inhibitor binding, gene fusions 3 8 7 or alternative splicing 9, 11-14, 17, 22-26, 54 understand the discrepancy among these RAF mutants. In this study, we systemically characterize all 3 9 5 RAF mutants with β 3-αC loop deletions, and provide solid evidence that this type of mutations activates 3 9 6
RAFs through improving homodimerization, which clarifies the controversial between those two groups.
9 7
Among RAF isoforms, BRAF and CRAF have been shown to function as both 3 9 8 catalysis-competitive kinases and allosteric activators 21 , while ARAF has a bare activity and been 3 9 9
thought as a scaffold 55, 56 and a MEK-docking platform in its catalysis process. This is further supported by that the kinase-dead 4 2 5
BRAF mutant with high dimer affinity is not able to activate downstream MEK-ERK pathway through 4 2 6
wild-type RAF molecules if it cannot bind MEK (Fig7A-B) . These findings suggest that the MEK-docking 4 5 0
Wild-type, BRAF -/and CRAF -/-MEFs were generated in previous study 58, 59 . Melanoma cell lines: All cell lines were maintained in DMEM medium with 10% FBS (Hyclone). Cell transfection were 4 5 7
carried out by using the Biotool transfection reagent and following the manufacturer's protocol. To 4 5 8
generate stable cell lines that express RAF or MEK1 mutants, viruses were prepared and applied to 4 5 9
infect target cells according to our previous studies 20, 36, 37, 60, 61 We thank the laboratories of Dr. Hui, Dr. Sabapathy, Dr. Virshup, and Dr. Anand for their help in 5 1 0 experimental technologies. We also thank Dr. Andrey Shaw and Dr. Susan Taylor for their assistances.
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